This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NW Bio Teams With The American Red Cross In DCVax® Program

 

BETHESDA, Md., Feb. 21, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it has entered into an agreement with the American Red Cross to provide blood collection services through which immune cells are obtained to make DCVax®-L treatments for brain cancer patients.  The services are focused initially on the Company's ongoing Phase II clinical trial for newly diagnosed Glioblastoma multiforme, the most lethal form of brain cancer.

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

DCVax®-L is an active immune therapy made from two main ingredients:  master immune cells (dendritic cells) from the patient's own immune system, and biomarkers from the patient's own tumor tissue collected at the time of surgery.  Precursors of the dendritic cells are in regular circulation in a patient's blood.  These precursor cells are collected through a blood draw (leukapheresis). To make DCVax®-L, the precursor cells are matured into a fresh set of master immune cells (dendritic cells) that have not been compromised by the patient's cancer. 

The Red Cross is the largest single supplier of blood and blood products in the United States, collecting and processing more than 40 percent of the nation's blood supply and distributing it to some 3,000 hospitals and transfusion centers nationwide. With a nationwide network of approximately 250 fixed blood collection sites across the United States, the Red Cross covers a wide geographic area and provides expertise in blood collection.

"We are excited to join forces with the American Red Cross to bring the benefits of their expertise and broad network to our patients," commented Linda Powers, CEO of NW Bio.  "Our Company's plan is to bring DCVax® not only to major medical centers but to patients all across the country, in the communities where they live, both in our current clinical trial and when DCVax® reaches the market. Adding the extensive network of Red Cross blood centers adds another major building block towards our goal."

Rich Feliciano, Red Cross Vice President, Business Development and Integration for Biomedical Services, commented, "The Red Cross is pleased to support Northwest Biotherapeutics' Phase II clinical trial of DCVax®-L for patients with Glioblastoma multiforme. We believe that the field of cellular therapy has great potential to have a positive impact on the lives of patients, and we look forward to working together during Northwest Biotherapeutics' study and potentially into the future. With our extensive network of fixed blood collection sites, the Red Cross can provide blood collections in support of Northwest Biotherapeutics' clinical trial across the United States."

 

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs